全文获取类型
收费全文 | 7623篇 |
免费 | 512篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 71篇 |
儿科学 | 175篇 |
妇产科学 | 210篇 |
基础医学 | 1065篇 |
口腔科学 | 371篇 |
临床医学 | 849篇 |
内科学 | 1505篇 |
皮肤病学 | 172篇 |
神经病学 | 836篇 |
特种医学 | 158篇 |
外科学 | 689篇 |
综合类 | 36篇 |
一般理论 | 9篇 |
预防医学 | 859篇 |
眼科学 | 103篇 |
药学 | 545篇 |
中国医学 | 24篇 |
肿瘤学 | 489篇 |
出版年
2024年 | 8篇 |
2023年 | 120篇 |
2022年 | 213篇 |
2021年 | 401篇 |
2020年 | 235篇 |
2019年 | 308篇 |
2018年 | 333篇 |
2017年 | 267篇 |
2016年 | 266篇 |
2015年 | 323篇 |
2014年 | 431篇 |
2013年 | 488篇 |
2012年 | 772篇 |
2011年 | 756篇 |
2010年 | 389篇 |
2009年 | 321篇 |
2008年 | 475篇 |
2007年 | 483篇 |
2006年 | 401篇 |
2005年 | 353篇 |
2004年 | 253篇 |
2003年 | 214篇 |
2002年 | 203篇 |
2001年 | 22篇 |
2000年 | 10篇 |
1999年 | 24篇 |
1998年 | 18篇 |
1997年 | 14篇 |
1996年 | 12篇 |
1995年 | 7篇 |
1994年 | 5篇 |
1993年 | 11篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1990年 | 5篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1978年 | 2篇 |
1975年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有8166条查询结果,搜索用时 15 毫秒
61.
Context
The fear-avoidance model was developed in an attempt to explain the process by which “pain experience” and “pain behavior” become dissociated from the actual pain sensation in individuals who manifest the phenomenon of exaggerated pain perception. High levels of fear avoidance can lead to chronic pain and disability and have successfully predicted rehabilitation time in the work-related–injury population. Existing fear-avoidance questionnaires have all been developed for the general population, but these questionnaires may not be specific enough to fully assess fear avoidance in an athletic population that copes with pain differently than the general population.Objective
To develop and validate the Athlete Fear Avoidance Questionnaire (AFAQ).Design
Qualitative research to develop the AFAQ and a cross-sectional study to validate the scale.Patients or Other Participants
For questionnaire development, a total of 8 experts in the fields of athletic therapy, sport psychology, and fear avoidance were called upon to generate and rate items for the AFAQ. For determining concurrent validity, 99 varsity athletes from various sports participated.Data Collection and Analysis
A total of 99 varsity athletes completed the AFAQ, the Fear-Avoidance Beliefs Questionnaire, and the Pain Catastrophizing Scale. We used Pearson correlations to establish concurrent validity.Results
Concurrent validity was established with significant correlations between the AFAQ and the Fear Avoidance Beliefs Questionnaire-Physical Activity (r = 0.352, P > .001) as well as with the Pain Catastrophizing Scale (r = 0.587, P > .001). High internal consistency of our questionnaire was established with a Cronbach α coefficient of 0.805. The final version of the questionnaire includes 10 items with good internal validity (P < .05).Conclusions
We developed a questionnaire with good internal and external validity. The AFAQ is a scale that measures sport-injury–related fear avoidance in athletes and could be used to identify potential psychological barriers to rehabilitation.Key Words: fear-avoidance model, scale, sports, athletic injuries, rehabilitation, psychologyKey Points
- We developed and validated the Athlete Fear Avoidance Questionnaire to assess pain-related fear in athletes.
- Pain-related fear or fear avoidance plays a critical role in the rehabilitation of patients with low back pain and work-related injuries. High levels of fear avoidance in athletes may affect rehabilitation times.
62.
Developing and Testing of a Software Prototype to Support Diagnostic Reasoning of Nursing Students 下载免费PDF全文
63.
Manuel R. Mazenauer Stole Manov Vanessa M. Galati Philipp Kappeler Jürgen Stohner 《RSC advances》2018,8(6):2872
Correction for ‘Synthetic routes for a variety of halogenated (chiral) acetic acids from diethyl malonate’ by Manuel R. Mazenauer et al., RSC Adv., 2017, 7, 55434–55440.An incorrect email address was provided for affiliation a, the correct version, along with capitalisation of Zürich in affiliation b, is shown below.The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers. 相似文献
64.
Masliza Mahmod Nikhil Pal Jennifer Rayner Cameron Holloway Betty Raman Sairia Dass Eylem Levelt Rina Ariga Vanessa Ferreira Rajarshi Banerjee Jurgen E. Schneider Christopher Rodgers Jane M. Francis Theodoros D. Karamitsos Michael Frenneaux Houman Ashrafian Stefan Neubauer Oliver Rider 《Journal of cardiovascular magnetic resonance》2018,20(1):88
Background
Heart failure (HF) is characterized by altered myocardial substrate metabolism which can lead to myocardial triglyceride accumulation (steatosis) and lipotoxicity. However its role in mild HF with preserved ejection fraction (HFpEF) is uncertain. We measured myocardial triglyceride content (MTG) in HFpEF and assessed its relationships with diastolic function and exercise capacity.Methods
Twenty seven HFpEF (clinical features of HF, left ventricular EF >50%, evidence of mild diastolic dysfunction and evidence of exercise limitation as assessed by cardiopulmonary exercise test) and 14 controls underwent 1H-cardiovascular magnetic resonance spectroscopy (1H-CMRS) to measure MTG (lipid/water, %), 31P-CMRS to measure myocardial energetics (phosphocreatine-to-adenosine triphosphate - PCr/ATP) and feature-tracking cardiovascular magnetic resonance (CMR) imaging for diastolic strain rate.Results
When compared to controls, HFpEF had 2.3 fold higher in MTG (1.45?±?0.25% vs. 0.64?±?0.16%, p?=?0.009) and reduced PCr/ATP (1.60?±?0.09 vs. 2.00?±?0.10, p?=?0.005). HFpEF had significantly reduced diastolic strain rate and maximal oxygen consumption (VO2 max), which both correlated significantly with elevated MTG and reduced PCr/ATP. On multivariate analyses, MTG was independently associated with diastolic strain rate while diastolic strain rate was independently associated with VO2 max.Conclusions
Myocardial steatosis is pronounced in mild HFpEF, and is independently associated with impaired diastolic strain rate which is itself related to exercise capacity. Steatosis may adversely affect exercise capacity by indirect effect occurring via impairment in diastolic function. As such, myocardial triglyceride may become a potential therapeutic target to treat the increasing number of patients with HFpEF.65.
Kazimierz O. Wrzeszczynski Vanessa Felice Avinash Abhyankar Lukasz Kozon Heather Geiger Dina Manaa Ferrah London Dino Robinson Xiaolan Fang David Lin Michelle F. Lamendola-Essel Depinder Khaira Esra Dikoglu Anne-Katrin Emde Nicolas Robine Minita Shah Kanika Arora Olca Basturk Vaidehi Jobanputra 《The Journal of molecular diagnostics : JMD》2018,20(6):822-835
66.
67.
Vanessa Pirani Gaioso Antonia Maria Villarruel Lynda Anne Wilson Andres Azuero Gwendolyn Denice Childs Susan Lane Davies 《Revista latino-americana de enfermagem》2015,23(3):500-511
OBJECTIVE:
to test a theoretical model based on the Parent-Based Expansion of the Theory of Planned Behavior examining relation between selected parental, teenager and cultural variables and Latino teenagers'' intentions to engage in sexual behavior.METHOD:
a cross-sectional correlational design based on a secondary data analysis of 130 Latino parent and teenager dyads.RESULTS:
regression and path analysis procedures were used to test seven hypotheses and the results demonstrated partial support for the model. Parent familism and knowledge about sex were significantly associated with parents'' attitudes toward sexual communication with their teenagers. Parent Latino acculturation was negatively associated with parents'' self-efficacy toward sexual communication with their teenagers and positevely associated with parents'' subjective norms toward sexual communication with their teenagers. Teenager knowledge about sex was significantly associated with higher levels of teenagers'' attitudes and subjective norms about sexual communication with parents. Only the predictor of teenagers'' attitudes toward having sex in the next 3 months was significantly associated with teenagers'' intentions to have sex in the next 3 months.CONCLUSION:
the results of this study provide important information to guide future research that can inform development of interventions to prevent risky teenager sexual behavior among Latinos. 相似文献68.
Ofir Moreno Todd Butler Vanessa Zann Ashley Willson Pui Leung Alyson Connor 《Clinical therapeutics》2018,40(11):1855-1867
Purpose
ME-401 is a novel selective inhibitor of phosphatidylinositol 3 kinase p110δ, an enzyme often found overexpressed and overactive in B-cell malignancies. The current study was performed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending oral doses of ME-401 in healthy volunteers.Methods
This analysis was an open-label, nonrandomized study in healthy male volunteers. Three sequential groups were dosed. Each group received single doses of ME-401 on two occasions; the doses tested ranged from 10 to 150 mg. Blood was drawn at various time points to analyze plasma concentrations of ME-401 and inhibition of basophil activation, a marker of phosphatidylinositol 3 kinase p110δ inhibition.Findings
Fifteen subjects received a single dose of ME-401 on two occasions. Three adverse events that were considered possibly related to the study drug were reported: one event of pain, one event of headache, and one event of upper abdominal pain. ME-401 exhibited dose proportionality up to 60 mg, and supra-proportional increases in exposure were observed above doses of 60 mg. In addition, there was a dose-proportional increase in the inhibition of basophil activation up to 60 mg. Mean t1/2 ranged from 9.36 to 29.23 hours across the dose range. A 60 mg dose of ME-401 approached 90% inhibition of basophil activation, and thereafter no further increase to the percent inhibition of basophil activation was observed for higher doses. Once-daily dosing of 60 mg ME-401 was forecasted to result in trough plasma levels exceeding the concentration needed for 90% inhibition of basophil activation.Implications
This first-in-human study showed that ME-401 was well tolerated after single doses up to 150 mg. Pharmacologic activity was confirmed after administration of single ascending oral doses of 10 to 150 mg. ME-401 60 mg, administered once daily, was selected as the starting dose for patient studies. ClinicalTrials.gov identifier: NCT02521389. 相似文献69.
70.